Circassia Pharmaceuticals, Inc.

BOSTON and MONTREAL, Dec. 19, 2023 /PRNewswire/ - enGene Holdings Inc. ("enGene,"Nasdaq: ENGN), a clinical-stage genetic medicines company whose lead program is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the appointment of Lota S. Zoth, CPA, as a member of the Board of Directors and Audit Committee Chair. "The addition of Lota to our Board is another milestone in our progression as a public genetic medicines company, and we are fortunate to welcome her counsel and depth of experience as a leader," said Jason D. Hanson, Chief Executive Officer of enGene. "Lota's distinguished history of operational and financial leadership strengthens our Board of Directors, and we look forward to her perspective and insights as we advance our pivotal trial of EG-70 in NMIBC, as well as our mission to mainstream gene therapy for the benefit of underserved patients." Ms. Zoth has more than two decades of experience in senior financial and accounting roles, including as Senior Vice President and Chief Financial Officer of MedImmune, Inc. and Senior Vice President, Controller and Chief Accounting Officer of PSINet, Inc. She also spent nearly a decade with Ernst & Young leading auditing efforts for flagship clients. Ms. Zoth is an experienced Board of Directors member, having served in various roles at other companies, including Board Chair, Lead Independent Director, and Audit Committee Chair, as well as on Compensation, Transaction, Finance and Special Strategic Committees. She is currently serving on the Boards of the publicly traded companies Lumos Pharma, Inovio Pharmaceuticals, and 89 Bio. Her past Board experience includes Zymeworks, Spark Therapeutics, Aeras, Orexigen Therapeutics, Circassia Pharmaceuticals, Hyperion Therapeutics, and Ikaria. "enGene is a truly differentiated company with a compelling vision, promising pipeline, and near-term potential to have a meaningful impact in the lives of patients living with BCG-unresponsive NMIBC," said Ms. Zoth. "I am honored to join the Board of Directors and to serve as Audit Committee Chair to help build a successful future for enGene and patients in need." About enGene enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene's lead program is EG-70 for patients with non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG), a disease posing a high clinical burden. EG-70 is being evaluated in an ongoing Phase 2 pivotal study. EG-70 was developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. enGene became a publicly traded company effective November 1, 2023, upon the completion of a business combination with Forbion European Acquisition Corporation, a special purpose acquisition company. For more information, visit enGene.com. Forward-Looking Statements Some of the statements contained in this press release may constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, and "forward-looking information" within the meaning of Canadian securities laws (collectively, "forward-looking statements"). enGene's forward-looking statements include, but are not limited to, statements regarding enGene's expectations, hopes, beliefs, intentions, goals, strategies, forecasts and projections. The words "anticipate", "appear", "approximate", "believe", "continue", "could", "estimate", "expect", "foresee", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "seek", "should", "would", and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements may include, for example, statements about: enGene's goal of mainstreaming gene therapy, enGene's product pipeline and the near-term potential to have a meaningful impact in the lives of patients living with BCG-unresponsive NMIBC. Many factors, risks, uncertainties and assumptions could cause the Company's actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the Company's ability to recruit and retain qualified scientific and management personnel, establish clinical trial sites and patient registration for clinical trials and acquire technologies complimentary to, or necessary for, its programs; the Company's ability to address diseases with high clinical needs; the Company's ability to retain commercial rights to EG-70 in the United States and commercialize EG-70 independently, while selectively partnering outside of the United States; the Company's plans and ability to secure regulatory approval, to execute product development, manufacturing process development, preclinical and clinical development efforts successfully and on anticipated timelines; enGene's ability to design mainstream gene therapy and bring genetic medicines to community clinics across the globe; and other risks and uncertainties detailed in filings with Canadian securities regulators on SEDAR+ and with the U.S. Securities and Exchange Commission ("SEC") on EDGAR, including those described in the "Risk Factors" section of the Company's Current Report on Form 8-K, filed with the SEC on October 31, 2023 (copies of which may be obtained at sedarplus.ca or ). You should not place undue reliance on any forward-looking statements, which speak only as of the date on which they are made. enGene anticipates that subsequent events and developments will cause enGene's assessments to change. While enGene may elect to update these forward-looking statements at some point in the future, enGene specifically disclaims any obligation to do so, unless required by applicable law. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. SOURCE enGene

None  Welcome to this week's (and last week's) Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word—or the bad—from your shop to Max Bayer or Gabrielle Masson, and we will feature it here at the end of each week.  Bayer backs Anderson for CEO role, Bauman slated to depart Bayer Bayer AG made a seismic hire this week, naming former Roche pharmaceutical chief Bill Anderson as the company’s new CEO. The news comes just two months after Anderson announced his departure from the company. As a result, current Bayer chief Werner Baumann will depart his post early, pacifying investors who felt he hasn’t been up to snuff. The move caps off a 35-year career for Baumann at Bayer.  The addition of Anderson marks a concerted refocusing on the company’s pharmaceutical and drug development pursuits, attempting to leave behind a reputation marred by the acquisition of Monsanto. Bayer noted in its announcement that Anderson was involved in the launch of 25 new medicines.  The move also reignites debate over whether the company’s consumer health and agricultural businesses should stay linked under one life sciences umbrella. Activist investors have advocated that the two be split up. Any reconsideration of the matter is still months away at least, with Anderson not slated to officially take the reins until June. Fierce Pharma Astellas implements new leadership strategy, tapping CSO Okamura for chief exec role Astellas Pharma Astellas Pharma has found its next leader within its internal constellation of executives, naming Chief Strategy Officer Naoki Okamura as the company’s new CEO. His promotion to the top role comes after 37 years at the company. Simultaneously, current CEO Kenji Yasukawa is moving into the chairman role, closing out five years as CEO. Replacing Okamura as strategy chief will be VP of corporate strategy Adam Pearson.  Okamura helped orchestrate a number of critical business development moves, including acquiring Audentes for $3 billion in 2019 and CAR-T company Xyphos for $665 million. The company also inked a couple of new partnerships last month, including an antibody research collaboration with Twist Biosciences.  Under Yasukawa’s leadership, Astellas moved away from focusing on specific disease areas and instead took a more multifaceted approach. And it appears to be paying off, as the company announced a 17% increase in revenue over the last nine months compared to the nine-month period a year earlier. Fierce Pharma Nelson wraps up eight month stint as head of White House science and tech wing White House Alondra Nelson is departing the White House Office of Science and Technology Policy at the end of the week, wrapping up two years at the office, eight months of which were as leader. She was appointed to lead the office after Eric Lander was ousted following allegations of bullying and fostering a toxic work environment.  Prior to filling the leadership vacuum left by Lander, Nelson ran the Science and Society team within the larger OSTP branch. The Science and Society unit was created under the Biden administration.  Much of Nelson’s work centered around designing ethical policy around artificial intelligence and improving transparency in federally-funded research. She spearheaded the creation of the Blueprint for an AI Bill of Rights, an in-depth framework regarding the use of AI in society and its implications.  She’ll be returning to the Institute for Advanced Study in Princeton, New Jersey, where she was a social science professor before joining the Biden administration. Tweet > Johnson & Johnson is overhauling operations for its Janssen pharmaceutical unit, with sweeping layoffs expected to claim staffers' jobs across the globe. Part of the so-called “comprehensive review” of its portfolio includes plans to operate its vaccines and infectious diseases outfits as one group. Consequently, James Merson, Ph.D., current head of the infectious disease unit, is set to leave the company “to pursue his next opportunity” while Penny Heaton, M.D., head of the existing vaccines division, will oversee the merged unit. Fierce Pharma > Iya Khalil, Ph.D., will be jumping from Novartis to Merck & Co., starting in her new role as VP and head of data, AI and genome sciences on Feb. 13. At Novartis, Khalil worked as global head of the AI Innovation Laboratory and has more than 20 years of experience pioneering AI/ML work, according to an emailed statement a Merck spokesperson sent Fierce Biotech.   > Three months after Rubius Therapeutics slashed most of its staff, Chief Scientific Officer Laurence Turka, M.D., stepped down. Turka—who also served as head of research and translational medicine—was joined by three board members, who also resigned. In November, CEO and President Dannielle Appelhans was set to leave in January, though Appelhans has now agreed to stay on until March 3. After former CEO Pablo Cagnoni and former Chief Financial Officer Pepe Carmona exited in November, Appelhans is set to be the only C-suite executive left. Release    > As Magenta Therapeutics winds down, a long list of C-suite executives have hit the exits. That includes CEO Jason Gardner, Chief Technical Officer David Nichols, Chief Commercial Officer Caren Deardorf, Chief People Officer Kristen Stants and Senior Vice President and Head of Clinical Development Shawn Rose. Gardner, Nichols and Deardorf will stay somewhat involved in as-needed consulting roles. The stem cell transplant biotech has also cut 56 positions, or 84% of staff, in an effort to save money. Fierce Biotech   > Ovid Tx has tapped Eisai’s Manoj Malhotra, M.D., as its chief medical officer and Takeda’s Toshiya Nishi to serve as head of epilepsy research. During his time at Takeda, Malhotra led global medical affairs for its epilepsy and multiple sclerosis units. Malhotra has held roles at Mallinckrodt Pharmaceuticals, Takeda Pharmaceutical and within Novartis Medical Affairs. Nishi also most recently worked at a Big Pharma, serving as a scientist in neuroscience drug discovery and translational medicine for Takeda. He also worked for Ovid as a visiting research fellow for two years starting in 2017. Release   > Former Viridian Therapeutics CEO and President Jonathan Violin, Ph.D., has stepped down, though he will serve as a company consultant for one year. In his place steps Scott Myers, who most recently served as AMAG Pharmaceuticals’ president and CEO from April 2020 until its acquisition by Covis Group in October 2020. Myers has plenty of CEO experience, previously holding the top title across several biotechs, including Rainier Therapeutics (formerly BioClin Therapeutics), Cascadian Therapeutics (acquired by Seattle Genetics) and Aerocrine (acquired by Circassia Pharmaceuticals). Release   > Adam Crystal, M.D., Ph.D., will leave his role as chief medical officer at C4 Therapeutics on Feb. 24, to pursue an opportunity as a head of R&D. Crystal has been C4’s CMO since 2019 and, before that, worked at Novartis Institutes for Biomedical Research. Upon his departure, Solid Therapeutics co-founder and biotech consultant Hagop Youssoufian, M.D., will serve as interim CMO. Release  > After a 70% workforce reduction in January and reprioritizing its pipeline, Cyteir is eliminating the roles of chief business officer and chief scientific officer. CBO Andrew Gengos departed Feb. 3, while CSO Paul Secrist, Ph.D., plans to leave April 1. Release > Blue Water Vaccines is bringing on Frank Jaeger to serve as  SVP of marketing and business development. Jaeger joins from Clarus Therapeutics, where he was SVP and chief commercial officer, and helped take the company public last spring. Release   > 2seventy bio Chief Operating Officer Nicola Heffron will be leaving the biotech next month, effective March 10. Release   > General manager of Novo Nordisk’s U.K. operations Pinder Sahota has decided to resign from his role as president of the Association of the British Pharmaceutical Industry (ABPI). The decision was made in efforts to avoid distracting from ABPI’s work amid an ongoing Novo Nordisk ABPI Code of Practice case. ABPI Vice President Susan Rienow, president of Pfizer UK, will temporarily take on the president’s roles and responsibilities until a new leader is chosen. Release   > Clinical-stage Adiso Therapeutics has appointed Srikar Guntaka, M.D., to the company’s newly created role of medical director. Most recently, Guntaka served as medical director and clinical development lead at Mirum Pharmaceuticals. He also has worked in positions at AbbVie and Baxter Healthcare. Release  > Harlan Weisman, M.D., has been selected to helm TFF Pharmaceuticals as permanent CEO. The former interim CEO has served as the company’s vice chair since 2018. In the past, he served as Flame Biosciences’ co-founder, CEO, president and chair, and was also former co-founder and chief scientific officer for Mycrobiomics. Earlier in his career, Weisman worked with J&J. Release   > Orchestra BioMed is conducting several organizational changes, tapping several new additions for its senior leadership team. Avi Fischer, M.D., joins from ElectroPhysiology Frontiers, where he was CEO, to serve as Orchestra's SVP of medical affairs and innovation, while J.C. Simeon joins from Amring Pharmaceuticals to take on the role of SVP of quality. Meanwhile, former SVP of Quality George Papandreou, Ph.D., will become Orchestra’s general manager and SVP of focal therapies. Lastly, previous Senior Director of Formulation Development Kunal Faldu has been promoted to serve as VP of pharmaceutical development. Release   > T-knife Therapeutics has cut to the chase, appointing Behzad Kharabi, M.D., to serve as chief medical officer for the immunotherapy company. Kharabi joins from Gilead’s Kite, where he led global clinical development for TECARTUS, an approved cell-based gene therapy for treating relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Before Kite, Kharabi worked for J&J’s Janssen Pharmaceuticals. Release  > Palisade Bio has promoted Robert McRae, who joined the company in 2021, as SVP of operations and strategic development, to chief operating officer. Before Palisade, McRae held several leadership positions at Viracta Therapeutics. Release

The increase in the Severe Asthma market size is a direct consequence of the expected launch of potential therapies an increase in the diagnosed prevalent population of Severe Asthma and increasing demand for personalized therapies. LAS VEGAS, June 8, 2022 /PRNewswire/ -- DelveInsight's Severe Asthma Market Insights report proffers a detailed comprehension of Severe Asthma market size by treatment, epidemiology, emerging therapies, market share of the individual therapies, current and forecasted Severe Asthma market size from 2019 to 2032 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan). Some of the salient features from the Severe Asthma Market Report : As per DelveInsight's analysis, the Severe Asthma market size in the 7MM was valued at almost USD 6 Billion in 2021 and is anticipated to grow at a CAGR of 5% for the study period (2019-2032). Key Severe Asthma companies such as GSK, AstraZeneca, Avillion, 4D Pharma, Avalo Therapeutics, Biosion, Roche, GenenTech, Boehringer Ingelheim Pharmaceuticals, Amgen, Pfizer, AB Science, Teva Pharmaceuticals, Sanofi, Regeneron Pharmaceuticals, Pieris Pharma, Novartis, Theravance Biopharma, and others are reported to bring a significant shift in the Severe Asthma market. The Severe Asthma emerging therapies that are expected to launch in the forecast period include GSK3511294, PT010, PT027, CSJ117, MRx-4DP0004, RG6173, CBP-201, PRS-060/AZD1402, BSI-045B, AVTX-002, and others. As per DelveInsight, the United States has the highest percentage of Severe Asthma patients pool among the 7MM. In addition to that, according to DelveInsight's analysts among the EU5 countries, the United Kingdom has the largest patient population of Severe Asthma, whereas Spain had the lowest patient population of Severe Asthma. Assessments as per DelveInsight's analysts indicate that Asthma diagnosed prevalence was more in adults than in pediatrics in the 7MM. The development of well-designed, randomized, controlled non-crossover trials with the potential benefits for Severe Asthma patients will drive the market growth in the forecast period. Also, approval and entry of new drugs will change the Severe Asthma market dynamics in the future. For further information on market impact by therapies, download the Severe Asthma market sample @ Severe Asthma Therapeutics Market Scenario Severe Asthma Overview Asthma is the most common chronic respiratory disease all over the globe. It affects the airways in the lungs, which become inflamed and narrowed due to various triggers, making it harder for air to flow out. It is a complex activity between airway inflammation and airway remodelling that results in airway hyper-responsiveness (AHR), which further leads to variable and excessive airway contraction. The characteristic Asthma symptoms include wheezing, shortness of breath, cough, a sensation of tightness in the chest, straining of neck and chest muscles, rapid breathing, and changes in heart rate. Asthma classification can be broadly done into intermittent or persistent. Here, Persistent asthma is further sub-divided based on severity into mild, moderate, and severe. Severe Asthma occurs due to various genetic, environmental, and psychological factors as well as respiratory infections. Severe Asthma symptoms appear often in the nighttime with a persistent airflow obstruction with a forced expiratory volume (FEV1) of less than 60% predicted before treatment. Based upon response to treatment, Severe Asthma is further classified into type-2 inflammation and non-type-2 inflammation. Type-2 inflammation includes allergic asthma and eosinophilic asthma (or e-asthma) while non-type-2 inflammation includes non-eosinophilic asthma. Severe Asthma Epidemiology Segmentation As per the assessment of DelveInsight, the total diagnosed prevalent (adult + pediatric) cases of Asthma in the 7MM was observed to be approximately 54 million cases in 2021. These cases are expected to increase by 2032. As per DelveInsight's estimates, among 7MM, the United States had the highest diagnosed cases of adult Asthma with almost 20 million cases in 2021. The Severe Asthma Market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into Total Diagnosed Prevalent (adult + pediatric) Cases of Asthma Severity-specific Diagnosed Prevalent Cases of Asthma Type-specific Diagnosed Prevalent Cases of Severe Asthma Learn more about the Severe Asthma Population Trends for the 7 MM by downloading @ Severe Asthma Epidemiology Forecast Report Severe Asthma Market Outlook The fundamental goal of Asthma therapy is to minimize airway inflammation and also reduce the Asthma symptoms that come with it. To limit the likelihood of exacerbation, guidelines-based care focuses on illness severity and selecting the right medicinal therapy. Inhaled corticosteroids are the most common chronic asthma treatment, but quick-relief (reliever) or rescue medications are frequently used to reduce acute Asthma symptoms. Short-acting beta-agonists (SABAs) relieve airway bronchoconstriction quickly and are indicated as a symptom-relieving rescue drug. If asthma still isn't under control, long-acting beta 2 agonists (LABA), montelukast, or theophylline are added. If Asthma symptoms and flare-ups persist, oral corticosteroids are prescribed. There are currently six US FDA approved monoclonal antibodies for add-on biological Severe Asthma treatment. They include Cinqair (reslizumab) Teva Pharmaceutical, Dupixent (dupilumab) Sanofi, and Regeneron, Fasenra (benralizumab) AstraZeneca/Kyowa Kirin, Tezspire (tezepelumab) AstraZeneca and Amgen, Nucala (mepolizumab) GlaxoSmithKline, and Xolair (omalizumab) Novartis/Genentech. Several new severe asthma therapeutic options are currently being developed. The key assets include GSK3511294 (Depemokimab) by GlaxoSmithKline, PT010 (Breztri/Trixeo/BGF MDI (budesonide-glycopyrrolate-formoterol inhalation)) by AstraZeneca, and PT027 (BDA MDI/Budesonide/albuterol sulfate metered-dose inhaler) by AstraZeneca and Bond Avillion. They are in the late stage of development and are expected to launch in the forecasted period (2022-2032). Several other companies are also developing drugs for Severe Asthma treatment including Novartis (CSJ117), 4D pharma (MRx-4DP0004), Roche (RG6173), Pieris Pharma, and AstraZeneca (PRS-060/AZD1402), Biosion (BSI-045B), among others. Discover more about therapy set to grab substantial Severe Asthma market share @ Severe Asthma Market Landscape Severe Asthma Pipeline Therapies and Key Companies GSK3511294 (Depemokimab): GlaxoSmithKline PT010: AstraZeneca PT027: AstraZeneca and Avillion CSJ117: Novartis MRx-4DP0004: 4D pharma RG6173: Roche PRS-060/AZD1402: Pieris Pharma and AstraZeneca BSI-045B: Biosion AVTX-002: Avalo Therapeutics To know about more pipeline therapies covered in the report, visit @ Severe Asthma Pipeline Analysis, Clinical Trials, and Emerging Therapies Severe Asthma Market Dynamics Severe Asthma market growth in the coming years is dependent on several factors such as an increase in the diagnosed prevalent population of Severe Asthma and increasing demand for personalized therapies. Also, the development of well-designed, randomized, controlled non-crossover trials with the potential benefits for patients will drive the Severe Asthma market growth in the forecast period. In addition to that, approvals and entry of new drugs will change the Severe Asthma market dynamics in the future. Several pharmaceutical giants are investigating drugs for Severe Asthma treatment with an improved diagnostic approach leading to a rise in the Severe Asthma market in the coming years. On the other hand, a lack of effective specific treatments in non-eosinophilic asthma (NEA) can represent an orphan asthma endotype serving as a drawback in the Severe Asthma market growth. Other factors such as a high cost of treatment, limitations in diagnosis, incorrect inhaler techniques, and poor adherence to treatment can all be considered as potential barriers to the rise of the Severe Asthma market. Know which therapy is expected to score the touchdown first @ Severe Asthma Market Landscape and Forecast Scope of the Severe Asthma Market Report Study Period: 2019-2032 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Severe Asthma Companies: GSK, AstraZeneca, Avillion, 4D Pharma, Avalo Therapeutics, Biosion, Roche, Amgen, Avalo Therapeutics, Teva Pharmaceuticals, Sanofi, Regeneron Pharmaceuticals, Pieris Pharma, Novartis, and many others. Key Severe Asthma Pipeline Therapies: GSK3511294, PT010, PT027, CSJ117, MRx-4DP0004, RG6173, PRS-060/AZD1402, BSI-045B, AVTX-002, and others Severe Asthma Therapeutic Assessment: Severe Asthma current marketed and emerging therapies Severe Asthma Market Dynamics: Severe Asthma market drivers and barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Unmet Needs, KOL's views, Analyst's views, Severe Asthma Market Access and Reimbursement Request for a Webex demo of the report @ Severe Asthma Therapeutics Market Table of Contents Get in touch with our Business executive @ Severe Asthma Market Landscape Analysis Related Reports Asthma Market DelveInsight's "Asthma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Asthma, historical and forecasted epidemiology, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. Allergic Asthma due to Dermatophagoides Farinae Market DelveInsight's "Allergic Asthma due to Dermatophagoides Farinae- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Allergic Asthma due to Dermatophagoides Farinae, historical and forecasted epidemiology, current Allergic Asthma due to Dermatophagoides Farinae treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. Eosinophilic Asthma Market DelveInsight's "Eosinophilic Asthma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Eosinophilic Asthma, historical and forecasted epidemiology, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. Asthma Epidemiology DelveInsight's 'Asthma - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Asthma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Pulse Oximeters Market DelveInsight's 'Pulse Oximeters Market Insights, Competitive Landscape and Market Forecast - 2027' report deliver an in-depth understanding of Pulse Oximeters, historical and forecasted Pulse Oximeters market trends, market drivers, market barriers, and key companies involved like Medtronic, Nonin Medical Inc, Lepu Medical Technology, TytoCare Ltd, VYAIRE, OMRON Corporation. Meditech Equipment Co ., Ltd, and several others. Cough Assist Devices Market "DelveInsight's 'Cough Assist Devices Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Cough Assist Devices and the historical and forecasted Cough Assist Devices market trends, market drivers & barriers, unmet needs and key companies involved such as Koninklijke Philips N.V, Percussionaire Corp., Emerson, Hill Rom, Dima Italia SRL, and many more. Cough in Idiopathic Pulmonary Fibrosis Market DelveInsight's 'Cough in Idiopathic Pulmonary Fibrosis (IPF)-Market Insights, Epidemiology and Market Forecast– 2032' report delivers an in-depth understanding of the cough in IPF, historical and forecasted epidemiology as well as the Cough in IPF market trends, market drivers & barriers, unmet needs and key companies involved such as Algernon Pharmaceuticals, Trevi Therapeutics, Nerre Therapeutics, and others. Chronic Obstructive Pulmonary Disease Market DelveInsight's 'Chronic Obstructive Pulmonary Disease (COPD)-Market Insights, Epidemiology, and Market Forecast–2032' report deliver an in-depth understanding of the Chronic Obstructive Pulmonary Disease (COPD), historical and forecasted epidemiology as well as the Chronic Obstructive Pulmonary Disease (COPD) market trends, market drivers & barriers, unmet needs and key companies involved such as AstraZeneca, Amgen, Circassia Pharmaceuticals Inc, Biomarck Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Chiesi Farmaceutici, Genentech, GlaxoSmithKline, Theravance, Innoviva, Inmunotek, Mereo BioPharma, Novartis Pharmaceuticals, and several others. Asthma Diagnostic Devices Market "DelveInsight's 'Asthma Diagnostic Devices Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Asthma Diagnostic Devices and the historical and forecasted Asthma Diagnostic Devices market trends, drivers, barriers, and key companies involved such as Medline Industries, Becton, Dickinson and Company, Siemens Process Instrumentation, Smiths Medical, Vyaire Medical, Nihon Kohden Corporation, Vitalograph, Circassia Limited, Intermedical (UK) Limited, and several others. Chronic Obstructive Pulmonary Disease Treatment Devices Market "DelveInsight's 'Chronic Obstructive Pulmonary Disease Treatment Devices Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Chronic Obstructive Pulmonary Disease Treatment Devices and the historical and forecasted Chronic Obstructive Pulmonary Disease Treatment Devices market trends, drivers, barriers and key companies involved such as GlaxoSmithKline plc, Novartis AG, Merck & Co., Koninklijke Philips N.V, AstraZeneca, 3M, GF HEALTH PRODUCTS, Sunovion Pharmaceuticals Inc, Smiths Medical, Baxter, and others. Interested to know more about the breakthrough happenings? Take a look at the posts below Asthma: Rising Prevalence And The Key Challenges In The Management Chronic Refractory Cough Market and the Monopoly of the Over-The-Counter Drugs Alarming Growth of Chronic Respiratory Diseases (CRDs) and Their Prolonged Impact on the Quality of Life About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Connect With Us at LinkedIn | Facebook | Twitter Contact Us Shruti Thakur [email protected] +1(919)321-6187 SOURCE DelveInsight Business Research, LLP